{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T18:08:30Z","timestamp":1763057310874},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,1,14]],"date-time":"2006-01-14T00:00:00Z","timestamp":1137196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1007\/s00228-005-0076-9","type":"journal-article","created":{"date-parts":[[2006,1,13]],"date-time":"2006-01-13T15:46:46Z","timestamp":1137167206000},"page":"173-177","source":"Crossref","is-referenced-by-count":7,"title":["Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran"],"prefix":"10.1007","volume":"62","author":[{"given":"Job","family":"Harenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"J\u00f6rg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,1,14]]},"reference":[{"issue":"3. suppl","key":"76_CR1","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","volume":"126","author":"J Ansell","year":"2004","unstructured":"Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists. The seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy. Chest 126(3. suppl):204S\u2013233S","journal-title":"Chest"},{"issue":"suppl","key":"76_CR2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.126.3_suppl.401S","volume":"126","author":"HR B\u00fcller","year":"2004","unstructured":"B\u00fcller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE (2004) Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(suppl):401\u2013428","journal-title":"Chest"},{"key":"76_CR3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1055\/s-0037-1613445","volume":"89","author":"BI Eriksson","year":"2003","unstructured":"Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M, METHRO III Study Group (2003) Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 89:288\u2013296","journal-title":"Thromb Haemost"},{"key":"76_CR4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00228-003-0565-7","volume":"59","author":"UG Eriksson","year":"2003","unstructured":"Eriksson UG, Bredberg U, Gislen K, Johansson LC, Frison L, Ahnoff M, Gustafsson D (2003) Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor. In young healthy male subjects. Eur J Clin Pharmacol 59:35\u201343","journal-title":"Eur J Clin Pharmacol"},{"key":"76_CR5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","volume":"362","author":"Executive Steering Committee on behalf of the SPORTIF III Investigators","year":"2003","unstructured":"Executive Steering Committee on behalf of the SPORTIF III Investigators (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691\u20131698","journal-title":"Lancet"},{"key":"76_CR6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","volume":"293","author":"J-N Fiessinger","year":"2005","unstructured":"Fiessinger J-N, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstrom T, Berkowitz SD, Nystrom P, Thorsen M, Ginsberg JS (2005) Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial. JAMA 293:681\u2013689","journal-title":"JAMA"},{"key":"76_CR7","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJMoa035162","volume":"349","author":"CW Francis","year":"2003","unstructured":"Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr, for the EXULT Study Group (2003) Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 349:1703\u20131712","journal-title":"N Engl J Med"},{"key":"76_CR8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","volume":"101","author":"D Gustafsson","year":"2001","unstructured":"Gustafsson D, Nystr\u00f6m J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, Bylund R (2001) The direct thrombin inhibitor melagatran and its oral prodrug H 376\/95; intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101:171\u2013181","journal-title":"Thromb Res"},{"key":"76_CR9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1055\/s-0037-1613886","volume":"83","author":"J Harenberg","year":"2000","unstructured":"Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, B\u00fcller HR, EASTERN-Investigators (2000) Fixed-dose, body weight-independent subcutaneous LMW Heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. Thromb Haemost 83:652\u2013656","journal-title":"Thromb Haemost"},{"key":"76_CR10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","volume":"340","author":"C Kearon","year":"1999","unstructured":"Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901\u2013907","journal-title":"N Engl J Med"},{"key":"76_CR11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","volume":"349","author":"C Kearon","year":"2003","unstructured":"Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinsson B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M, Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631\u2013639","journal-title":"N Engl J Med"},{"key":"76_CR12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1538-7836.2003.00060.x","volume":"1","author":"P Klement","year":"2003","unstructured":"Klement P, Carlsson S, Rak J, Liao P, Vlasion M, Staffod A, Johnston M, Weitz JI (2003) The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. J Thromb Haemost 1:587\u2013594","journal-title":"J Thromb Haemost"},{"key":"76_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-125-1-199607010-00001","volume":"125","author":"P Prandoni","year":"1996","unstructured":"Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1\u20137","journal-title":"Ann Intern Med"},{"key":"76_CR14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","volume":"348","author":"PM Ridker","year":"2003","unstructured":"Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ, PREVENT Investigators (2003) Long-term, long-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348:1425\u20131434","journal-title":"N Engl J Med"},{"key":"76_CR15","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1056\/NEJM199506223322501","volume":"332","author":"S Schulman","year":"1995","unstructured":"Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332:1661\u20131665","journal-title":"N Engl J Med"},{"key":"76_CR16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","volume":"349","author":"S Schulman","year":"2003","unstructured":"Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, THRIVE III Investigators (2003) Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349:1713\u20131721","journal-title":"N Engl J Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-005-0076-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-005-0076-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-005-0076-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:51:20Z","timestamp":1558702280000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-005-0076-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,14]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["76"],"URL":"https:\/\/doi.org\/10.1007\/s00228-005-0076-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,14]]}}}